CureDuchenne Webinar with Avidity Biosciences

CureDuchenne Webinar with Avidity Biosciences, a privately held biotech company pioneering a new class of precision medicines based upon antibody-oligonucleotide conjugates, to brief the Duchenne community about Avidity’s research in pre-clinical development of potential therapies to treat patients with Duchenne muscular dystrophy (DMD).  The Webinar will feature Debra Miller, founder and CEO, CureDuchenne and Arthur A. Levin, Ph.D., EVP of research and development, Avidity Biosciences.